Shraddha Y. Gaikwad

Shraddha Y. Gaikwad

Auto-generated profile, based on publicly available information

Shraddha Y. Gaikwad

Division of Virology, ICMR-National AIDS Research Institute, Pune, MH, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2024 in Heliyon
Verified
Journal Article
Open access
SRSmita Rakshit
Smita Rakshit
AMAshwini More
Ashwini More
SGShraddha Gaikwad
Shraddha Gaikwad
CSChandrabhan Seniya
Chandrabhan Seniya
AGAniket K Gade
Aniket K Gade
KKKapil Kamble
Kapil Kamble
Diosgenin, an essential sapogenin steroid with significant biological implications, is composed of a hydrophilic sugar moiety intricately linked to a hydrophobic steroid aglycone. While the antiviral properties of diosgenin against numerous RNA viruses have been extensively documented, its potential in combating Human Immunodeficiency Virus infections remains unexplored. This current investigation presents a comprehensive and systematic analysis of extracts derived from the leaves of Helicteres isora, which are notably enriched with diosgenin. Rigorous methodologies, including established chromatographic techniques and Fourier-transform infrared spectroscopy were employed for the characterization of the active diosgenin compound followed by molecular interaction analyses with the key HIV enzymes and mechanistic validation of HIV inhibition. The inhibitory effects of extracted diosgenin on the replication of HIV-1 were demonstrated using a permissive cellular system, encompassing two distinct subtypes of HIV-1 strains. Computational analyses involving molecular interactions highlighted the substantial occupancy of critical active site pocket residues within the key HIV-1 proteins by diosgenin. Additionally, the mechanistic underpinnings of diosgenin activity in conjunction with standard controls were elucidated through specialized colorimetric assays, evaluating its impact on HIV-1 Reverse Transcriptase and Integrase enzymes. To our current state of knowledge, this study represents the inaugural demonstration of the anti-HIV efficacy inherent to diosgenin found in the leaves of Helicteres isora, and can be taken further for drug design and development for the management of HIV infection.

4 May 2023 in Heliyon
Verified
Journal Article
Open access
SGShraddha Y. Gaikwad
Shraddha Y. Gaikwad
PPPallavi Phatak
Pallavi Phatak
AMAnupam Mukherjee
Anupam Mukherjee
The advent of Highly Active Antiretroviral Therapy has majorly contributed towards reducing the morbidity and mortality associated with HIV infected people, thus improving the quality of their life. Still, the eradication of HIV infection has not been achieved due to some important limitations such as non-adherence to therapy, cellular toxicity, restricted bioavailability of antiretroviral drugs and emergence of drug resistant viruses. Moreover, persistence of latent HIV-reservoirs even under antiviral-drug pressure is the major obstacle in HIV cure. Currently used antiretrovirals can suppress the viral replication in activated CD4+ cells, however, it has been observed that the available antiretroviral therapy appears inadequate to reduce latent reservoirs established in resting memory CD4+ T cells. Therefore, for eradication or reduction of latent reservoirs many immunotherapeutic and pharmacologic approaches including latency reversing agents are being studied constantly. Additionally, promising therapeutic strategies including discovery of novel drugs and drug targets are continuously being explored. Therefore, preclinical testing has become an important step of drug development process, continuously demanding innovative, but less time consuming evaluation strategies. Present review attempts to gather and line-up the information on existing cell-based methodologies applied for assessing drug candidates for their antiretroviral potential. Further, we intend to outline the advanced and reliable cell based methodologies that would expedite the process of discovery and development of antiretrovirals.

16 October 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
STShivani Tyagi
Shivani Tyagi
SGShraddha Y. Gaikwad
Shraddha Y. Gaikwad
MTMadhuri chandane Tak
Madhuri chandane Tak
AMAnupam Mukherjee
Anupam Mukherjee
SKShobhit Kumar
Shobhit Kumar

6 June 2024 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
AMAbdul Muheem
Abdul Muheem
MWMohd Waseem
Mohd Waseem
ASAli Sartaj
Ali Sartaj
SGShraddha Gaikwad
Shraddha Gaikwad
AMAshwini More
Ashwini More
JAJaved Ali
Javed Ali

18 December 2023 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
STShivani Tyagi
Shivani Tyagi
SBSanjula Baboota
Sanjula Baboota
SGShraddha Y. Gaikwad
Shraddha Y. Gaikwad
JAJaved Ali
Javed Ali
AMAnupam Mukherjee
Anupam Mukherjee
SKShobhit Kumar
Shobhit Kumar

12 June 2026 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
R HARSHITHKUMARR HARSHITHKUMAR
R HARSHITHKUMAR
PJPratiksha Jadaun
Pratiksha Jadaun
CSChandrabhan Seniya
Chandrabhan Seniya
SGShraddha Y. Gaikwad
Shraddha Y. Gaikwad
AMAshwini More
Ashwini More
AMAnupam Mukherjee
Anupam Mukherjee